|
summary: In this 24-month, double-blind, randomised clinical trial, the efficacy of oral fingolimod relative to placebo in people with relapsing-remitting MS was investigated. As compared with placebo, oral fingolimod improved the relapse rate, the risk of disability progression, and MRI outcomes. However, further studies are needed to assess the safety and efficacy of oral fingolimod on the long term.
authors: Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; the FREEDOMS Study Group.
source: N Engl J Med. 2010 Jan 20
weblink: click here
category: Clinical Trials and Therapeutics
related research news: click here
glossary:
ACE
Clinical trial
Disability
Magnetic Resonance Imaging (MRI)
Multiple sclerosis
Placebo
Randomised
Relapse
Relapsing/remitting MS
Sclerosis
|
